Citadel Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$206M Buy
1,481,200
+350,700
+31% +$49.1M 0.03% 444
2025
Q4
$139M Sell
1,130,500
-16,300
-1% -$1.98M 0.02% 670
2025
Q3
$127M Sell
1,146,800
-399,800
-26% -$45.4M 0.02% 692
2025
Q2
$171M Buy
1,546,600
+312,900
+25% +$33.3M 0.03% 471
2025
Q1
$138M Buy
1,233,700
+464,500
+60% +$47.9M 0.03% 521
2024
Q4
$71.1M Sell
769,200
-540,200
-41% -$48.6M 0.01% 982
2024
Q3
$110M Buy
1,309,400
+165,700
+14% +$12.6M 0.02% 647
2024
Q2
$78.5M Buy
1,143,700
+258,400
+29% +$17.2M 0.02% 824
2024
Q1
$64.8M Sell
885,300
-161,000
-15% -$12.4M 0.01% 1016
2023
Q4
$84.8M Sell
1,046,300
-381,000
-27% -$29.6M 0.02% 787
2023
Q3
$107M Sell
1,427,300
-153,100
-10% -$11.8M 0.02% 602
2023
Q2
$122M Buy
1,580,400
+124,300
+9% +$9.91M 0.03% 514
2023
Q1
$121M Sell
1,456,100
-688,900
-32% -$57.1M 0.03% 533
2022
Q4
$184M Sell
2,145,000
-644,500
-23% -$51M 0.04% 362
2022
Q3
$172M Sell
2,789,500
-786,500
-22% -$49.6M 0.04% 369
2022
Q2
$221M Sell
3,576,000
-546,900
-13% -$33.9M 0.06% 249
2022
Q1
$245M Buy
4,122,900
+1,137,100
+38% +$72.7M 0.05% 268
2021
Q4
$217M Buy
2,985,800
+282,200
+10% +$19.4M 0.04% 315
2021
Q3
$189M Sell
2,703,600
-270,100
-9% -$19M 0.04% 363
2021
Q2
$205M Buy
2,973,700
+816,300
+38% +$54.5M 0.05% 309
2021
Q1
$139M Buy
2,157,400
+364,700
+20% +$23.5M 0.03% 435
2020
Q4
$104M Sell
1,792,700
-1,050,300
-37% -$63.4M 0.03% 524
2020
Q3
$180M Buy
2,843,000
+205,000
+8% +$14.2M 0.05% 230
2020
Q2
$203M Buy
2,638,000
+232,100
+10% +$17.8M 0.07% 179
2020
Q1
$180M Buy
2,405,900
+151,200
+7% +$10.4M 0.08% 160
2019
Q4
$147M Buy
2,254,700
+761,400
+51% +$49.6M 0.06% 263
2019
Q3
$94.6M Sell
1,493,300
-536,600
-26% -$35.1M 0.04% 423
2019
Q2
$137M Buy
2,029,900
+354,400
+21% +$23.3M 0.06% 272
2019
Q1
$109M Sell
1,675,500
-1,024,300
-38% -$68.1M 0.05% 332
2018
Q4
$169M Buy
2,699,800
+1,083,700
+67% +$75.7M 0.09% 160
2018
Q3
$125M Sell
1,616,100
-335,800
-17% -$25.4M 0.06% 330
2018
Q2
$138M Buy
1,951,900
+258,900
+15% +$18.3M 0.07% 265
2018
Q1
$128M Sell
1,693,000
-23,800
-1% -$1.89M 0.07% 235
2017
Q4
$123M Sell
1,716,800
-199,300
-10% -$15.1M 0.07% 261
2017
Q3
$155M Sell
1,916,100
-287,000
-13% -$21.9M 0.12% 135
2017
Q2
$156M Buy
2,203,100
+762,000
+53% +$50.7M 0.13% 120
2017
Q1
$97.9M Sell
1,441,100
-241,700
-14% -$17M 0.09% 208
2016
Q4
$121M Buy
1,682,800
+207,900
+14% +$15.5M 0.12% 125
2016
Q3
$117M Buy
1,474,900
+98,500
+7% +$8M 0.12% 129
2016
Q2
$115M Buy
1,376,400
+176,900
+15% +$15.7M 0.13% 120
2016
Q1
$110M Buy
1,199,500
+472,400
+65% +$42.6M 0.14% 107
2015
Q4
$73.6M Sell
727,100
-224,200
-24% -$23.3M 0.08% 267
2015
Q3
$93.4M Buy
951,300
+105,500
+12% +$11.7M 0.09% 224
2015
Q2
$99M Buy
845,800
+544,400
+181% +$59.5M 0.09% 239
2015
Q1
$29.6M Sell
301,400
-166,300
-36% -$16.9M 0.03% 758
2014
Q4
$44.1M Sell
467,700
-215,100
-32% -$22.2M 0.04% 531
2014
Q3
$72.7M Buy
682,800
+64,300
+10% +$6.3M 0.08% 267
2014
Q2
$51.3M Sell
618,500
-224,500
-27% -$17.5M 0.06% 359
2014
Q1
$59.7M Buy
843,000
+201,900
+31% +$15.8M 0.07% 333
2013
Q4
$48.2M Sell
641,100
-26,500
-4% -$1.85M 0.06% 373
2013
Q3
$42M Buy
667,600
+168,600
+34% +$10.1M 0.06% 381
2013
Q2
$25.6M Buy
+499,000
New +$26M 0.04% 528

Other funds holding GILD

Citadel Advisors's GILD Position: Q1 2026 in Review

Citadel Advisors increased its Gilead Sciences (GILD) stake by 2.4% in Q1 2026, buying an estimated $13.3M and bringing the position to 3,982,185 shares worth $555M. The position accounts for 0.09% of the portfolio, ranked #156.

Citadel Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $607M in Q2 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Citadel Advisors held 3,982,185 shares of Gilead Sciences worth $555M as of Q1 2026.
  • Citadel Advisors bought 94,665 Gilead Sciences shares in Q1 2026, an estimated $13.3M.
  • Gilead Sciences made up 0.09% of Citadel Advisors's portfolio in Q1 2026, its #156 holding.
  • Citadel Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Gilead Sciences position peaked at $607M in Q2 2025.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.